Endotoxin testing aligned to harmonised USP <85>
Ergopharm has aligned its Bacterial Endotoxins Test procedures to the harmonised general chapter USP <85>, following the coming into effect of the internationally agreed compendial text. The change consolidates a single, consistent endotoxin limit and method framework across the sterile-injectable range manufactured at the Ergopharm Advanced Research Centre, Vadodara.
USP general chapter <85> Bacterial Endotoxins Test, together with its counterparts in the European and Japanese pharmacopoeias, became the officially harmonised text effective 1 December 2012. Harmonisation means the three principal pharmacopoeias now describe the same Limulus Amebocyte Lysate (LAL) approach, the same method for calculating the endotoxin limit, and the same preliminary tests for interfering factors. For a manufacturer producing for export, this removes long-standing differences in wording and calculation between compendia and allows one validated method to serve each of them.
“A single harmonised endotoxin chapter lets one validated method support release across the pharmacopoeias, reducing method divergence for products intended for export.”
In practical terms, Ergopharm has updated its analytical procedures so that the endotoxin limit for each parenteral product is derived from the harmonised relationship between the threshold pyrogenic dose and the maximum recommended human dose per kilogram per hour, and so that the maximum valid dilution is documented explicitly in every method. The test for interfering factors is applied product by product: each formulation is screened for enhancement or inhibition of the lysate reaction, and the validated dilution is recorded before routine release testing begins.
The harmonised chapter recognises gel-clot, turbidimetric and chromogenic techniques. Ergopharm retains the gel-clot method as its referee test where a result is in question, consistent with the chapter's own hierarchy, while using photometric methods where they offer suitable sensitivity and throughput. Endotoxin control sits alongside the sterility test under USP <71> as part of the release specification for injectable products, and results are reported on the Certificate of Analysis for each batch.
The alignment has been managed through Ergopharm's change-control system. Revised standard operating procedures, updated method-validation records and analyst re-training have been documented, and the change reviewed under the company's pharmaceutical quality system before implementation. The measures described concern Ergopharm's own testing and release processes; all figures and limits are product-specific and illustrative of the harmonised framework rather than any national marketing authorisation.
Key facts
- Harmonised text effective
- 1 December 2012 (USP / EP / JP <85>)
- Method basis
- Limulus Amebocyte Lysate (LAL)
- Recognised techniques
- Gel-clot (referee), turbidimetric, chromogenic
- Related release test
- Sterility USP <71>; reported on CoA
This notice describes Ergopharm’s own packaging and processes and how they follow published standards; it does not assert a specific national marketing approval.